Completed Research Projects

    Characterizing and Predicting Drug Effect on Cognition. (NIH/NINDS). PI: Susan Marino

2019-2021 PhaseI/IIA Clinical Trials of Multivalent Opioid Vaccine Components.  (NIH/NIDA UG3 DA047711). PIs: Sandra Comer, Maro Pravetoni; Co-Investigator, Angela Birnbaum

2017-2018 Cognitive effects of IR vs XR Topiramate (Trokendi® XR) in Patients with Migraine. Supernus. PI: Susan Marino; Co-Investigator: Angela Birnbaum

2017-2018    Comparison of the cognitive and motor effects of treatment between an immediate- and extended-release tacrolimus (Envarsus® XR) based immunosuppression regimen in kidney transplant recipients, Veloxis Pharmaceuticals. PI: Susan Marino; Co-Investigator: Angela Birnbaum

2016-2018    Pharmacokinetic and Cognitive Side Effects of Cannabidiol in Adult Patients, Epilepsy Foundation.  PIs: Angela Birnbaum/Susan Marino. 

2015-2020   Vaccines for Prescription Opioid and Heroin Abuse, U01DA038876, PI: Paul Pentel, Co-Investigator: Angela Birnbaum. 

2015             Advanced Training in Pharmacometric Approaches, PI: Angela Birnbaum.

2014-2016    Cognitive Effects of Vinpocetine in Healthy Adults & Epilepsy Patients: Assay Validation, PI: Susan Marino; Co-Investigator: Angela Birnbaum.

2013-2015    Cognitive and Motor Effects of Treatment with a Calcineurin Inhibitor (Tacrolimus) versus Belatacept in Kidney Transplant Patients, Bristol Myers Squibb, PI: Susan Marino.

2012-2018    Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) (U01 NS038455-11A1 PIs: Kimford Meador, Page Pennell, 2U01 NS050659-06A1 PI: Nancy Browning NINDS/NICHD) Pharmacokinetics Core Director/U of MN PI: Angela Birnbaum.

2012-2016 Characterizing and Predicting Drug Effect on Cognition (NIH/NINDS R01 NS076665) PI: Susan Marino

2012-present   Pharsight-University of Minnesota Pharmacometrics Collaboration, Pharsight Corporation. Competitive renewal. PI: Angela Birnbaum.

2012-2018    Characterizing and Predicting Drug Effect on Cognition (NIH/NINDS R01NS076665), PI: Susan Marino; Co-Investigator: Angela Birnbaum.

2012  Shimadzu Scientific Instruments Grant, LCMSMS, Role: PI

2011-2016  Pharmacogenomics and Pharmacokinetics of Lamotrigine in Early Pregnancy, Epilepsy Foundation, Role: PI

2010-2015 Preclinical Studies of a Heroin/Morphine Vaccine for Opiate Addiction NIH/NIDA, Role: Co-Investigator.

2010-2013  Pharsight-University of Minnesota Pharmaceutics Collaboration, Pharsight Corporation, Role:  PI

2008-2013 Multivalent Vaccine for Opiate Addiction, NIH/NIDA, Role: Co-Investigator.

2007-2013  Clinical Impact of Unstable AED Levels in Elderly Nursing Home Epilepsy Patients, 5R01AG026390, Role: PI

2007-2010  Determination of Bioavailability and Clearance of Lamotrigine-XR by a Stable-Isotope Technique, GlaxoSmithKline, Role: Co- Investigator

2002-2008  Population Pharmacokinetics of the Newer Antiepileptic Drugs in Elderly Epilepsy Patients. Project 3 within NIH program project grant, P50 NINDS NS16308, title "Epilepsy Clinical Research Program”. Role: PI

2002-2008  Effects of Age, Gender, and Race on the Metabolism of Antiepileptic Drugs, Project 1 within NIH program project grant (P50 NINDS NS16308) title "Epilepsy Clinical Research Program”. Role: Co- Investigator 

2002-2008  Effect of Aging on Glucuronidation of AEDs, Project 2 within NIH program project grant, P50 NINDS NS16308, title "Epilepsy Clinical Research Program”. Role: Co- Investigator

2004  Bioavailability and Side Effect of Rectally Administered Oxcarbazepine Suspension, Novartis, Role: Co- Investigator 

1999-2001  Absorption and Side Effects of Rectally Administered Topiramate, RW Johnson. Role Co-PI 

1999  Gabapentin in a Dynorphin pain mouse model, Parke-Davis-declined. Role:  PI (Declined due to contract issues.)

1999  Tiagabine in mouse models of acute and chronic pain, Abbott Laboratories, Role: PI

1999  Determination of the Hepatic Cytochrome P450 Involved in the Metabolism of Thiotepa in Humans Children, Cancer Research Fund (CCRF), Role: Co-Investigator. 

1999  Real-Time Quantitative PCR Detection System, NIH, Role: Co-Investigator 

1997-2002  Pharmacokinetics And Metabolism Of Antiepileptic Drugs In Elderly Patients, NIH P50 Program Project Grant (NINDS-NS16308) title "Pharmacokinetics and metabolism of antiepileptic drugs in elderly patients", Role:  PI. 

1997-2002  Population pharmacokinetics of antiepileptic drugs in the elderly.  Project 2 within NIH program project grant (P50 NINDS NS16308) title "Factors affecting AED elimination in elderly nursing home patients" Role: PI. 

1998-1999  Tiagabine in a Dynorphin pain mouse model, Abbott Laboratories. Role: PI. 

1998-1999  Rapid Infusion of Intravenous Valproate (Depacon®) in Children With Epilepsy, Abbott Laboratories. Role: PI. 

1997-1999  Comparison of Absorption of Lamotrigine (Lamictal®) After Oral vs. Rectal Administration (Compressed Tablet): Glaxo Wellcome. Role: PI. 

1997-1999  Comparison of Absorption of Lamotrigine (Lamictal®) After Oral vs. Rectal Administration (Dispersible Tablet): Glaxo Wellcome. Role: PI. 

1996-1997  Genetics of Antiepileptic Medication Metabolism and the Sudden Death Syndrome, NIH P50 Program Project Grant (NINDS-NS16308), Role: Co- Investigator

1995-1996  Renewal, Determinants of Carbamazepine and Valproic Acid Hypometabolism, USP Fellowship Award. Role: PI

1994-1995  Determinants of Carbamazepine and Valproic Acid Hypometabolism, USP Fellowship Award, Role: PI

1994-1995  Carbamazepine in Young Children, Ciba-Geigy Pharmaceuticals. Role: PI